SIGA Technologies, Inc. submitted a New Drug Application to the FDA for its oral formulation of tecovirimat (Tpoxx) to treat smallpox, and also other orthopoxvirus infections. No cure or treatment for smallpox exists.
The advanced development of Tpoxx was funded by the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA). Pursuant to a contract with BARDA, SIGA has successfully delivered 2 million courses of tecovirimat to the Strategic National Stockpile.